Accolade (NASDAQ:ACCD) Price Target Lowered to $13.00 at Stifel Nicolaus

Accolade (NASDAQ:ACCDFree Report) had its price objective cut by Stifel Nicolaus from $15.00 to $13.00 in a research note issued to investors on Monday, Benzinga reports. They currently have a buy rating on the stock.

ACCD has been the topic of several other research reports. Barclays initiated coverage on Accolade in a report on Wednesday, January 3rd. They set an equal weight rating and a $13.00 price objective on the stock. SVB Leerink initiated coverage on Accolade in a report on Monday, February 26th. They set an outperform rating and a $16.00 price objective on the stock. William Blair reaffirmed an outperform rating on shares of Accolade in a report on Tuesday, January 9th. Leerink Partnrs reiterated an outperform rating on shares of Accolade in a research report on Monday, February 26th. Finally, Raymond James upped their target price on shares of Accolade from $12.00 to $16.00 and gave the company an outperform rating in a research report on Tuesday, January 9th. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and an average target price of $15.53.

Read Our Latest Analysis on ACCD

Accolade Stock Up 0.5 %

NASDAQ:ACCD opened at $9.40 on Monday. The stock’s fifty day moving average price is $9.83 and its two-hundred day moving average price is $9.92. Accolade has a 52-week low of $6.33 and a 52-week high of $17.00. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.35 and a current ratio of 2.35. The company has a market cap of $727.65 million, a price-to-earnings ratio of -5.70 and a beta of 2.08.

Institutional Trading of Accolade

A number of large investors have recently made changes to their positions in the company. Nordea Investment Management AB increased its position in shares of Accolade by 1.4% in the 3rd quarter. Nordea Investment Management AB now owns 106,764 shares of the company’s stock valued at $1,148,000 after buying an additional 1,423 shares in the last quarter. Handelsbanken Fonder AB increased its position in shares of Accolade by 14.8% in the 3rd quarter. Handelsbanken Fonder AB now owns 16,765 shares of the company’s stock valued at $177,000 after buying an additional 2,165 shares in the last quarter. BluePath Capital Management LLC bought a new stake in shares of Accolade in the 3rd quarter valued at $28,000. DekaBank Deutsche Girozentrale bought a new stake in shares of Accolade in the 3rd quarter valued at $28,000. Finally, Barclays PLC boosted its stake in Accolade by 10.8% in the 3rd quarter. Barclays PLC now owns 37,630 shares of the company’s stock worth $398,000 after purchasing an additional 3,671 shares during the period. Institutional investors own 84.99% of the company’s stock.

Accolade Company Profile

(Get Free Report)

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.

Read More

Analyst Recommendations for Accolade (NASDAQ:ACCD)

Receive News & Ratings for Accolade Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accolade and related companies with MarketBeat.com's FREE daily email newsletter.